Real-world outcomes for metastatic non-small cell lung cancer patients treated with checkpoint inhibitor immunotherapy in Canada.

Dimas Yusuf,Jenny J. Ko,Hyokeun Cho,Corey Sheremeto,Ying Wang,Rosalyn A. Juergens,Peter M. Ellis,Alkarim Billawala,Amin Kay,Swati Kulkarni,Tarek Elfiki,Rasna Gupta,Krista Naccarato,Alex Pennetti,Devalben Patel,Elliot Charles Smith,R Walton,M. Hurry,Geoffrey Liu,Winson Y. Cheung

Real-world outcomes for metastatic non-small cell lung cancer patients treated with checkpoint inhibitor immunotherapy in Canada.

2020

54Background: The majority of patients with non-small cell lung cancer (NSCLC) are diagnosed with incurable, metastatic disease. Immunotherapy (IO) agents have improved overall, long term survival....

Keywords:

Disease
Internal medicine
Lung cancer
non small cell
Immunotherapy
Oncology
Medicine
Pathology
long term survival
immune checkpoint inhibitors
real world outcomes

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations